Regeneron Pharmaceuticals (REGN) 10-K Summary — Year Ended Dec 31, 2024
Regeneron is a biopharmaceutical company that develops and commercializes drugs. The company's revenue increased in the latest period, and it reported strong operating income and cash flow.
Key takeaway
Year ended Dec 31, 2024 · FY2025 10-K
Regeneron is a biopharmaceutical company that develops and commercializes drugs. The company's revenue increased in the latest period, and it reported strong operating income and cash flow.
Financial snapshot
Selected annual figures reported with the filing, shown separately from the narrative summary.
Annual revenue
$14.2B
Revenue reported for the fiscal year.
Operating income
$4B
Income from operations reported for the year.
Net income
$4.4B
Net income reported for the year.
Operating cash flow
$4.4B
Cash generated by operating activities.
Annual revenue trend
Reported annual revenue and its change from the preceding fiscal year.
| Period ended | Revenue | Year-over-year change |
|---|---|---|
| Dec 31, 2021 | $16.1B | n/a |
| Dec 31, 2022 | $12.2B | -24.3% |
| Dec 31, 2023 | $13.1B | +7.8% |
| Dec 31, 2024 | $14.2B | +8.3% |
Business overview
The company focuses on drug discovery and development using technologies such as 'Trap' and VelociSuite, as well as newer modalities including gene silencing and editing. It also operates manufacturing facilities to produce its products.
Financial performance
Revenue declined from a prior high, then grew over the following periods, with the most recent period showing an increase. Operating income, net income, and cash from operations were all reported at robust levels.
Material risks
The company faces risks related to expanding manufacturing capacity, including high start-up costs, potential difficulties in process development, and the need to comply with regulatory standards for its facilities. These challenges could affect production yields and timelines.
Liquidity and capital
The company plans to allocate capital toward developing or acquiring additional manufacturing capabilities and may also invest in new drug development technologies and hiring personnel.
What to watch
Monitor the company's progress in scaling up manufacturing operations and achieving regulatory compliance for its facilities.